HIV infection begins when the virus envelope glycoprotein (Env) binds to CD4, the primary receptor molecule on the target cell surface. The virion membrane then fuses with the cell membrane, thus enabling the viral genetic material to enter the cell. Our previous work demonstrated that CD4 is not sufficient for fusion to occur; an additional """"""""fusion cofactor"""""""" is also required on the target cell. A related problem is that different genetic variants of HIV-1 have markedly distinct capabilities to infect different CD4-positive target cell types: some variants (macrophage-tropic) infect macrophages but not continuous T-lymphocyte cell lines; others (T-cell line-tropic) show the opposite specificity. The macrophage-tropic variants predominate during the early stage of infection and are the major types transmitted between individuals; the T-cell line-tropic variants appear as the infection progresses to the symptomatic stage, and probably play a special role in destruction of the immune system. Our previous work suggested that the cell type infection tropisms of different HIV variants are due the fusion specificities of the corresponding Envs. We also obtained evidence that these specificities are due to the preferential use by various Envs of distinct fusion cofactors that are differentially expressed on different CD4-expressing cell types. Using a novel cDNA screening procedure for fusion cofactor activity, we identified a molecule with properties of a fusion cofactor for T-cell line-tropic isolates; this molecule was designated """"""""fusin"""""""". Subsequently we identified another cofactor, CC CKR5, that functions preferentially for macrophage-topic variants. These cofactors appear to be members of the chemokine receptor subfamily of G protein-coupled receptors. Our findings represent major advances in our understanding of HIV entry; furthermore they suggest fundamentally new concepts about HIV transmission, disease progression, and possible means of treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000538-09
Application #
2566796
Study Section
Special Emphasis Panel (LVD)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1996
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Salzwedel, Karl; Berger, Edward A (2009) Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. Retrovirology 6:75
Berger, Edward A; Alkhatib, Ghalib (2007) HIV gp120 interactions with coreceptors: insights from studies with CCR5-based peptides. Eur J Med Res 12:403-7
Alkhatib, Ghalib; Berger, Edward A (2007) HIV coreceptors: from discovery and designation to new paradigms and promise. Eur J Med Res 12:375-84
Lusso, Paolo; Earl, Patricia L; Sironi, Francesca et al. (2005) Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79:6957-68
Lagenaur, Laurel A; Berger, Edward A (2005) An anti-HIV microbicide comes alive. Proc Natl Acad Sci U S A 102:12294-5
Agrawal, Lokesh; VanHorn-Ali, Zainab; Berger, Edward A et al. (2004) Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 103:1211-7
Dey, Barna; Del Castillo, Christie S; Berger, Edward A (2003) Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 77:2859-65
Farber, Joshua M; Berger, Edward A (2002) HIV's response to a CCR5 inhibitor: I'd rather tighten than switch! Proc Natl Acad Sci U S A 99:1749-51
McHugh, Louise; Hu, Stella; Lee, B K et al. (2002) Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J Biol Chem 277:34383-90
Schito, M L; Kennedy, P E; Kowal, R P et al. (2001) A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression. J Infect Dis 183:1592-600

Showing the most recent 10 out of 17 publications